Vitaxin

VitaxinMonoclonal antibody

Type| Whole antibody
Source| Humanized (from mouse)
Target| alpha-v beta-3 integrin
Clinical data
Trade names| Vitaxin
ATC code|

* none

Identifiers
ChemSpider|

* none

NY (what is this?)

Vitaxin (MEDI-523) is a humanized monoclonal antibody against the vascular integrin alpha-v beta-3.[1] It is shown to be a promising angiogenesis inhibitor used in the treatment of some forms of cancer. Vitaxin was in 2002 being studied for rheumatoid arthritis.[2] It is the developmental precursor of Etaracizumab (MEDI-522). Both are derived from the mouse antibody LM609.[3]

Vitaxin is safe for humans. It has little effect on advanced cancer.[3]

## References

1. ↑ "New paradigms for the treatment of cancer: the role of anti-angiogenesis agents". Advances in Cancer Research (Academic Press) 79: 1–38 (27). 2000. doi:10.1016/s0065-230x(00)79001-4. ISBN 978-0-12-006679-7. PMID 10818676. https://archive.org/details/advancesincancer0000unse_f3h8/page/27.
2. ↑ "Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases". Annals of the Rheumatic Diseases 61 (Suppl 2): ii96–ii99. November 2002. doi:10.1136/ard.61.suppl_2.ii96. PMID 12379637.
3. ↑ 3.0 3.1 "Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion". Clinical Cancer Research 11 (21): 7851–7860. November 2005. doi:10.1158/1078-0432.CCR-05-0262. PMID 16278408.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Vitaxin. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Vitaxin&oldid=246450"